Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2021 01/21/2021 01/22/2021 01/25/2021 01/26/2021 Date
125.14(c) 132.98(c) 131.02(c) 147(c) 152.88 Last
8 001 568 20 880 838 10 067 191 26 970 870 13 645 635 Volume
+0.10% +6.26% -1.47% +12.20% +4.00% Change
More quotes
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash position 2020 2 597 M - -
P/E ratio 2020 -120x
Yield 2020 -
Sales 2021 9 689 M - -
Net income 2021 5 144 M - -
Net cash position 2021 9 212 M - -
P/E ratio 2021 12,0x
Yield 2021 -
Capitalization 58 169 M 58 169 M -
EV / Sales 2020 109x
EV / Sales 2021 5,05x
Nbr of Employees 1 100
Free-Float 90,0%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
More about the company
Notations Surperformance© of Moderna, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MODERNA, INC.
01:46pJohnson & Johnson's Profit Is Boosted by Pharmaceuticals Business -- 2nd Upda..
DJ
01:29p44.3 MLN DOSES OF COVID-19 VACCINES : U.s. cdc
RE
01:08pPFIZER : Can COVID-19 vaccines be mixed and matched?
AQ
12:48pGAVI seeks political support for COVAX as rich nations strike fresh vaccine d..
RE
12:40pJ&J 4Q sales rise despite pandemic, but charges cut profits
AQ
12:10pEU drugs agency says it is offering advice to makers of Russian vaccine
RE
12:02pSOCIALIZING AFTER THE VACCINE : Experts say shot won't offer "free pass" right a..
AQ
11:50aMODERNA : Canadians who have had COVID-19 should still get the vaccine, experts ..
AQ
11:26aCanada's vaccine deliveries further threatened as Europe mulls export control..
AQ
09:03aJohnson & Johnson's Profit Is Boosted by Pharmaceuticals Business --Update
DJ
08:32aMODERNA : on Track to Deliver 100 Million Doses of COVID-19 Vaccine to US Govern..
MT
08:20aJohnson & Johnson Profit Is Boosted by Pharmaceuticals Business
DJ
08:05aMODERNA : Provides U.S. COVID-19 Vaccine Supply Update
BU
07:06aMODERNA : WHO issues Moderna vaccine dosage recommendations
AQ
02:46aGermany backs EU export restrictions on vaccine after supply cuts
RE
More news
News in other languages on MODERNA, INC.
01:47pROUNDUP 5 : Dritter Corona-Impfstoff in Sicht - aber wichtige offene Fragen
10:52aWDH : Corona-Infektionszahlen in Israel weiter hoch - Impfdaten machen Mut
09:46aSÖDER :  Kein Export von Corona-Impfstoffen außerhalb von Europa
09:44aVACCIN : Moderna en mesure de livrer 100 millions de doses aux USA au T1
09:43aRKI : Zwei Prozent der Bevölkerung in Deutschland gegen Corona geimpft
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 2020
The beginning of the move
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,93 $
Last Close Price 147,00 $
Spread / Highest target 25,9%
Spread / Average Target -6,17%
Spread / Lowest Target -53,1%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.2.15%35 090
SEAGEN INC.2.84%32 583
HANGZHOU TIGERMED CONSULTING CO.,LTD18.50%25 245